CASI Pharmaceuticals (CASIF) Return on Capital Employed (2024 - 2025)
CASI Pharmaceuticals (CASIF) reported Return on Capital Employed of 444.36% for Q4 2025, up 62289.0% on a YoY basis from N/an in Q4 2024, and up 14.2% quarter-over-quarter from 389.12% in Q3 2025.
CASI Pharmaceuticals (CASIF) Return on Capital Employed (2024 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported Return on Capital Employed for 2 years, with the latest figure at 444.36% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 62289.0% year-over-year to 444.36%; the trailing twelve-month figure through Dec 2025 stood at 444.36% (up 62289.0% YoY), and the FY2025 full-year result was 449.71%, up 59112.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 444.36%, up from 389.12% in the prior quarter.
- The five-year high for Return on Capital Employed was 444.36% in Q4 2025, with the low at 178.53% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - | - |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - | -107.40% |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - | - |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - | -50.43% |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | 444.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 444.36% |
| Sep 30, 2025 | 389.12% |
| Jun 30, 2025 | 193.90% |
| Mar 31, 2025 | 0.12% |
| Dec 31, 2024 | -178.53% |
| Jun 30, 2024 | 0.08% |
| Mar 31, 2024 | -13.36% |